Optimizing the management of chronic obstructive pulmonary disease: Applying the GOLD strategy

Clinical Practice

Volumn 10, Issue 4, 2013, Pages 481-492

  D'Urzo, Anthony ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACLIDINIUM BROMIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CARBOCISTEINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; INDACATEROL; INDACATEROL PLUS GLYCOPYRRONIUM; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; OLODATEROL; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; QVA 149; ROFLUMILAST; SALMETEROL; SHORT ACTING DRUG; THEOPHYLLINE; TIOTROPIUM BROMIDE; UMECLIDINIUM; UNCLASSIFIED DRUG; VILANTEROL;

ASTHMA; ATYPICAL MYCOBACTERIOSIS; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIABETES MELLITUS; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DYSPNEA; EARLY DIAGNOSIS; EVIDENCE BASED PRACTICE; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FRACTURE; HEALTH STATUS; HIGH RISK PATIENT; HUMAN; LUNG FUNCTION; MAINTENANCE THERAPY; MORBIDITY; MORTALITY; PNEUMONIA; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; RISK FACTOR; SPIROMETRY; SYMPTOMATOLOGY;

EID: 84880241139     PISSN: 20449038     EISSN: 20449046     Source Type: Journal    
DOI: 10.2217/cpr.13.38     Document Type: Review

References (84)

1. Lopez AD, Mathers CD. Measuring the global burden of disease and epidemiological transitions: 2002-2030. Ann. Trop. Med. Parasitol. 100(5-6), 481-499 (2006).
2. WHO. Global Surveillance, Prevention and Control of Chronic Respiratory Diseases: a Comprehensive Approach. Bousquet J, Khaltaev N (Eds.) WHO Press, Geneva, Switzerland (2007).
3. Mannino DM, Braman S. The epidemiology and economics of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 4(7), 502-506 (2007).
4. Takahashi T, Ichinose M, Inoue H, Shirato K, Hattori T, Takishima T. Underdiagnosis and undertreatment of COPD in primary care settings. Respirology 8(4), 504-508 (2003).
5. Agusti A, Calverley PM, Celli B etal. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir. Res. 11, 122 (2010).
6. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur. Respir.J. 33(5), 1165-1185 (2009).
7. Celli BR, Cote CG, Marin JM etal. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N. Engl. J.Med. 350(10), 1005-1012 (2004).
8. Cazzola M, MacNee W, Martinez FJ etal. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur. Respir.J. 31(2), 416-469 (2008).
9. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320(7245), 1297-1303 (2000).
10. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline LN. Development and first validation of the COPD assessment test. Eur. Respir.J. 34(3), 648-654 (2009).
11. Schlecht NF, Schwartzman K, Bourbeau J. Dyspnea as clinical indicator in patients with chronic obstructive pulmonary disease. Chron. Respir. Dis. 2(4), 183-191 (2005).
12. Voll-Aanerud M, Eagan TM, Wentzel-Larsen T, Gulsvik A, Bakke PS. Respiratory symptoms, COPD severity, and health related quality of life in a general population sample. Respir. Med. 102(3), 399-406 (2008).
13. Hurst JR, Vestbo J, Anzueto A etal. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J.Med. 363(12), 1128-1138 (2010)
14. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 54(7), 581-586 (1999).
15. Mahler DA, Ward J, Waterman LA, McCusker C, Zuwallack R, Baird JC. Patient-reported dyspnea in COPD reliability and association with stage of disease. Chest 136(6), 1473-1479 (2009).
16. Reda AA, Kotz D, Kocks JW, Wesseling G, van Schayck CP. Reliability and validity of the clinical COPD questionniare and chronic respiratory questionnaire. Respir. Med. 104(11), 1675-1682 (2010).
17. Trappenburg JC, Touwen I, de Weert-van Oene GH etal. Detecting exacerbations using the Clinical COPD Questionnaire. Health Qual. Life Outcomes 8, 102 (2010).
18. van der Molen T, Willemse BW, Schokker S, ten Hacken NH, Postma DS, Juniper EF. Development, validity and responsiveness of the clinical COPD questionnaire. Health Qual. Life Outcomes 1, (2003).
19. Appleton S, Poole P, Smith B, Veale A, Lasserson TJ, Chan MM. Long-acting b2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. (3), CD001104 (2006).
20. Barr RG, Bourbeau J, Camargo CA, Ram FS. Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. (2), CD002876 (2005).
21. Bateman ED, Ferguson GT, Barnes N etal. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur. Respir. J. doi:10.1183/09031936.00200212 (2013) (Epub ahead of print)
22. Mahler DA, D'Urzo A, Bateman ED etal. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 67(9, 781-788 (2012)
23. Cazzola M, Di MF, Santus P etal. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm. Pharmacol. Ther. 17(1), 35-39 (2004).
24. Cazzola M, Centanni S, Santus P etal. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir. Med. 98(12), 1214-1221 (2004).
25. Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 134(2), 255-262 (2008).
26. Tashkin DP, Donohue JF, Mahler DA etal. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir. Med. 103(4), 516-524 (2009).
27. van Noord JA, Aumann JL, Janssens E etal. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur. Respir.J. 26(2), 214-222 (2005).
28. Tashkin DP, Rennard SI, Martin P etal. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 68(14), 1975-2000 (2008).
29. Calverley P, Pauwels R, Vestbo J etal. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361(9356), 449-456 (2003).
30. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir.J. 22(6), 912-919 (2003).
31. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J.Respir. Crit. Care Med. 177(1), 19-26 (2008).
32. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374(9691), 685-694 (2009).
33. Fabbri LM, Calverley PM, Izquierdo-Alonso JL etal. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials. Lancet 374(9691), 695-703 (2009).
34. Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ. Superiority of triple therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 63(7), 592-598 (2008).
35. Zheng JP, Kang J, Huang SG etal. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet 371(9629), 2013-2018 (2008).
36. Steiropoulos P, Tzouvelekis A, Bouros D. Formoterol in the management of chronic obstructive pulmonary disease. Int. J.Chron. Obstruct. Pulmon. Dis. 3(2), 205-215 (2008).
37. Tashkin DP, Fabbri LM. Long-acting b-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir. Res. 11, 149 (2010).
38. Chapman KR, Rennard SI, Dogra A, Owen R, Lassen C, Kramer B. Long-term safety and efficacy of indacaterol, a long-acting b(2)-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest 140(1), 68-75 (2011).
39. Dahl R, Chung KF, Buhl R etal. Efficacy of a new once-daily long-acting inhaled b2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 65(6), 473-479 (2010).
40. Feldman G, Siler T, Prasad N etal. Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm. Med. 10, (2010).
41. Kornmann O, Dahl R, Centanni S etal. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur. Respir.J. 37(2), 273-279 (2011).
42. Buhl R, Dunn LJ, Disdier C etal. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur. Respir.J. 38(4), 797-803 (2011).
43. Donohue JF, Fogarty C, Lotvall J etal. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am. J.Respir. Crit. Care Med. 182(2), 155-162 (2010).
44. Rodrigo GJ, Neffen H. Comparison of indacaterol with tiotropium or twice-daily long-acting b-agonists for stable COPD: a systematic review. Chest 142(5), 1104-1110 (2012).
45. Korn S, Kerwin E, Atis S, Amos C, Owen R, Lassen C. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily inCOPD: a 12-week study. Respir. Med. 105(5), 719-726 (2011).
46. Casaburi R, Mahler DA, Jones PW etal. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir.J. 19(2), 217-224 (2002).
47. Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 124(5), 1743-1748 (2003).
48. Donohue JF, van Noord JA, Bateman ED etal. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 122(1), 47-55 (2002).
49. Beeh KM, Singh D, Di SL, Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int. J.Chron. Obstruct. Pulmon. Dis. 7, 503-513 (2012).
50. D'Urzo A, Ferguson GT, van Noord JA etal. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir. Res. 12, 156 (2011).
51. Kerwin E, Hebert J, Gallagher N etal. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur. Respir. J. 40(5), 1106-1114 (2012).
52. Vestbo J, Vogelmeier C, Creemers J, Falques M, Ribera A, Gil EG. Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD. COPD 7(5), 331-336 (2010).
53. Cazzola M, Molimard M. The scientific rationale for combining long-acting b2?agonists and muscarinic antagonists in COPD. Pulm. Pharmacol. Ther. 23(4), 257-267 (2010).
54. Jones PW, Donohue JF, Nedelman J, Pascoe S, Pinault G, Lassen C. Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis. Respir. Res. 12, 161 (2011).
55. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am. J.Respir. Crit. Care Med. 160(2), 542-549 (1999).
56. Vogelmeier CF, Bateman ED, Pallante J etal. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet. Respir. Med. 1(1), 51-60 (2013).
57. GlaxoSmithKline. GSK and Theravance announce positive results from four pivotal PhaseIII studies for once-daily LAMA/LABA (UMEC/VI) in COPD. Press Release. July 2012.
58. Aalbers R, Maleki-Yazdi MR, Hamilton A etal. Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat inhaler in patients with COPD. Eur. Respir.J. 40(Suppl.56), P2882S (2012).
59. Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur. Respir.J. 34(3), 757-769 (2009).
60. Jung KS, Park HY, Park SY etal. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respir. Med. 106(3), 382-389 (2012).
61. Welte T, Miravitlles M, Hernandez P etal. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am. J.Respir. Crit. Care Med. 180(8), 741-750 (2009).
62. Rabe KF. Update on roflumilast, a phosphodiesterase inhibitor for the treatment of chronic obstructive pulmonary disease. Br. J.Pharmacol. 163(1), 53-67 (2011).
63. Price D, Yawn B, Brusselle G, Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim. Care Respir.J. 22(1), 92-100 (2013).
64. Hanania NA, Darken P, Horstman D etal. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50microg) combined in the Diskus inhaler for the treatment of COPD. Chest 124(3), 834-843 (2003).
65. Mahler DA, Wire P, Horstman D etal. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am. J.Respir. Crit. Care Med. 166(8), 1084-1091 (2002).
66. Corda L, Bertella E, La Piana GE, Boni E, Redolfi S, Tantucci C. Inhaled corticosteroids as additional treatment in b-1-antitrypsin-deficiency-related COPD. Respiration 76(1), 61-68 (2008).
67. Tatsis G, Kotsifas K, Filaditaki V, Makrantoni G, Boulia S. Efficacy of beclomethasone dipropionate HFA 200 microg once daily in chronic obstructive pulmonary disease and bronchial asthma. J.Int. Med. Res. 35(3), 361-373 (2007).
68. Stewart JI, Criner GJ. The small airways in chronic obstructive pulmonary disease: pathology and effects on disease progression and survival. Curr. Opin. Pulm. Med. 19(2), 109-115 (2013).
69. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N. Engl. J.Med. 337(1), 8-14 (1997).
70. Guillot B. Adverse skin reactions to inhaled corticosteroids. Expert Opin. Drug Saf. 1(4), 325-329 (2002).
71. Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 66(8), 699-708 (2011).
72. Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 290(17), 2301-2312 (2003).
73. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am. J.Med. 123(11), 1001-1006 (2010).
74. Spencer S, Evans DJ, Karner C, Cates CJ. Inhaled corticosteroids versus long-acting b(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. (10), CD007033 (2011).
75. Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur. Respir. J. 34(1), 13-16 (2009).
76. Koichiro T. Pharmacotherapy options in COPD according to the new guidelines of the Japanese Respiratory Society. Jap. Med. J. 54(2), 105-109 (2011).
77. O'Donnell DE, Hernandez P, Kaplan A etal. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease-2008 update-highlights for primary care. Can. Respir. J. 15(Suppl.A), 1A-8A (2008).
78. Bellamy D, Smith J. Role of primary care in early diagnosis and effective management of COPD. Int. J.Clin. Pract. 61(8), 1380-1389 (2007).
79. Price DB, Yawn BP, Jones RC. Improving the differential diagnosis of chronic obstructive pulmonary disease in primary care. Mayo Clin. Proc. 85(12), 1122-1129 (2010).
80. D'Urzo AD, Tamari I, Bouchard J, Jhirad R, Jugovic P. New spirometry interpretation algorithm: primary care respiratory alliance of Canada approach. Can. Fam. Physician 57(10), 1148-1152 (2011).
81. O'Donnell DE, Laveneziana P. Physiology and consequences of lung hyperinflation in COPD. Eur. Respir. Rev. 15, 61-67 (2006).
82. Troosters T, Sciurba F, Battaglia S etal. Physical inactivity in patients with COPD, a controlled multi-center pilot-study. Respir. Med. 104(7), 1005-1011 (2010).
83. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 374(9696), 1171-1178 (2009).
84. Jenkins CR, Jones PW, Calverley PM etal. Efficacy of salmeterol/ fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir. Res. 10, (2009).